amofor GmbH

amofor GmbH is a pharmaceutical formulation company focused on enabling poorly soluble drug compounds through advanced thermodynamic modeling and targeted experimental development. Founded as a spin-off from TU Dortmund University, amofor combines deep scientific expertise with practical formulation know-how to support pharmaceutical companies in the development of stable and high-performance drug products.

The company specializes in amorphous solid dispersions (ASDs), co-amorphous systems, lipid-based formulations, and other bioavailability-enhancing technologies. Its core competence is the application of the PC-SAFT (Perturbed-Chain Statistical Associating Fluid Theory) model, one of the world’s leading thermodynamic frameworks for predicting molecular interactions, phase behavior, miscibility, stability, and process performance in pharmaceutical systems.

amofor develops both experimental and in-silico workflows to reduce trial-and-error experimentation, minimize API consumption, and accelerate formulation development. Through its proprietary SolCalc software platform, the company provides predictive tools for ASD stability, water sorption, glass transition behavior, crystallization risk, spray drying, solvent selection, and secondary drying optimization.

With more than 200 scientific publications and extensive industrial collaborations, amofor supports pharmaceutical partners from early screening to process optimization and long-term stability prediction. The company’s approach combines rigorous thermodynamics with practical pharmaceutical development to create faster, more reliable, and scientifically grounded formulation strategies.